5.68

2.35% -0.15

After Hours: 5.79 0.11 +1.94%

Wave Life Sciences Ltd (WVE)

Overview News Price History Option Chain Financials Why WVE Down? Discussions Forecast

Wave Life Sciences Ltd stock is traded at $5.68, with a volume of 2.67M. It is down -2.35% in the last 24 hours and down -13.48% over the past month. WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Previous Close:

$5.83

Open:

$5.91

24h Volume:

2.67M

Relative Volume:

0.56

Market Cap:

$1.09B

Revenue:

$71.80M

Net Income/Loss:

$-183.59M

P/E Ratio:

-5.3875

EPS:

-1.0543

Net Cash Flow:

$-186.52M

1W Performance:

-7.73%

1M Performance:

-13.48%

6M Performance:

-68.12%

1Y Performance:

-14.65%

1-Day Range:

$5.555

$5.93

1-Week Range:

$5.555

$6.309

52-Week Range:

$5.02

$21.73

Wave Life Sciences Ltd Stock (WVE) Company Profile

Name

Wave Life Sciences Ltd

Sector

Healthcare (1104)

Industry

Biotechnology (615)

Phone

617-949-2900

Address

7 STRAITS VIEW, SINGAPORE

Employee

317

Twitter

@WAVELifeSci

Next Earnings Date

2026-07-29

Latest SEC Filings

WVE's Discussions on Twitter

Compare WVE vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
WVE Wave Life Sciences Ltd	5.68	1.12B	71.80M	-183.59M	-186.52M	-1.0543
VRTX Vertex Pharmaceuticals Inc	499.65	124.70B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	631.81	66.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	912.46	55.17B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	192.62	38.71B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	293.55	38.90B	4.29B	577.22M	641.34M	4.2086

Wave Life Sciences Ltd Stock (WVE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-05-26	Initiated	BofA Securities	Buy
Dec-12-25	Reiterated	Wedbush	Outperform
Dec-09-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Oct-20-25	Initiated	Wells Fargo	Overweight
Aug-04-25	Initiated	Canaccord Genuity	Buy
Jul-28-25	Initiated	Oppenheimer	Outperform
Jul-16-25	Initiated	Citigroup	Buy
Jun-11-25	Resumed	Raymond James	Outperform
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Wedbush	Outperform
Feb-25-25	Initiated	Jefferies	Buy
Oct-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Sep-27-24	Resumed	JP Morgan	Overweight
Sep-19-24	Initiated	B. Riley Securities	Buy
Sep-09-24	Initiated	JP Morgan	Overweight
May-15-24	Initiated	Wells Fargo	Overweight
Dec-19-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Raymond James	Outperform
May-24-23	Downgrade	Jefferies	Buy → Hold
Dec-15-20	Resumed	H.C. Wainwright	Buy
Oct-23-20	Initiated	RBC Capital Mkts	Sector Perform
Dec-31-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-01-19	Initiated	Guggenheim	Buy
Jul-15-19	Initiated	Cowen	Market Perform
Apr-17-19	Reiterated	H.C. Wainwright	Buy
Aug-07-18	Initiated	Stifel	Buy
Jul-23-18	Initiated	H.C. Wainwright	Buy
Mar-19-18	Reiterated	Mizuho	Buy
Feb-15-17	Initiated	H.C. Wainwright	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Dec-07-15	Initiated	JMP Securities	Mkt Outperform
Dec-07-15	Initiated	Jefferies	Buy
Dec-07-15	Initiated	Leerink Partners	Outperform
Dec-07-15	Initiated	Sun Trust Rbsn Humphrey	Buy

View All

Wave Life Sciences Ltd Stock (WVE) Latest News

Jun 28, 2026

Price to earnings forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView

Jun 28, 2026

Jun 27, 2026

What Went Wrong For WVE? The Obesity Drug Trial Data That Spooked Investors - Stocktwits

Jun 27, 2026

Does Wave Life Sciences’ (WVE) RNA Obesity Program Signal a Shift in Its Competitive Positioning? - simplywall.st

Jun 27, 2026

Enterprise value to EBITDA forward of Wave Life Sciences Ltd. – NASDAQ:WVE - TradingView

Jun 27, 2026

Wave Life Sciences (WVE) shareholders approve Singapore Scheme for redomiciliation - Stock Titan

Jun 26, 2026

We Think Wave Life Sciences (NASDAQ:WVE) Can Afford To Drive Business Growth - Moomoo

Jun 26, 2026

Price to earnings forward of Wave Life Sciences Ltd. – DUS:1U5 - TradingView

Jun 26, 2026

Jun 25, 2026

Wave Life Sciences(WVE) Stock Options Chain | Quotes & News - Moomoo

Jun 25, 2026

Wave Life Sciences Ltd. Actuals & Estimates (NASDAQ:WVE) - TradingView

Jun 25, 2026

WVE Forecast — Price Target — Prediction for 2027 - TradingView

Jun 25, 2026

Wave Life Sciences initiates phase 2a obesity trial for WVE-007 By Investing.com - Investing.com Australia

Jun 25, 2026

Wave Life Sciences initiates phase 2a obesity trial for WVE-007 - Investing.com UK

Jun 25, 2026

Jun 24, 2026

Wave Life Sciences Announces Initiation of Phase 2a Portion of INLIGHT Trial of WVE-007 for Obesity and Cardiometabolic Diseases - Investing News Network

Jun 24, 2026